World Journal of Surgery

, Volume 36, Issue 11, pp 2637–2643 | Cite as

Survival Benefit of Palliative Gastrectomy in Gastric Cancer Patients with Peritoneal Metastasis

  • Masanori Tokunaga
  • Masanori Terashima
  • Yutaka Tanizawa
  • Etsuro Bando
  • Taiichi Kawamura
  • Hirofumi Yasui
  • Narikazu Boku



The survival benefit of palliative gastrectomy in patients with peritoneal metastasis as a single incurable factor remains unclear.


A total of 148 gastric cancer patients with peritoneal metastasis underwent gastrectomy or chemotherapy at the Shizuoka Cancer Center between September 2002 and December 2008 and were included in this study. The effects of gastrectomy and chemotherapy on their long-term outcome were investigated. Multivariate analysis was also performed to identify independent prognostic factors.


Gastrectomy was performed in 82 patients and subsequent chemotherapy was administered to 55. Chemotherapy was selected as an initial treatment for 66 patients. Median survival time (MST) was identical between patients with and without gastrectomy (13.1 vs. 12.0 months; P = 0.410). Conversely, MST was significantly longer in patients who received chemotherapy (13.7 months) than those who did not (7.1 months; P = 0.048). According to the results of multivariate analysis, chemotherapy (hazards ratio [HR] = 0.476; 95 % CI = 0.288–0.787) was selected as an independent prognostic factor, while gastrectomy was not.


The results of the present study did not show a survival benefit of palliative gastrectomy in selected patients with peritoneal metastasis. Instead, chemotherapy has to be considered as an initial treatment for these patients.


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRefGoogle Scholar
  2. 2.
    Kakeji Y, Maehara Y, Tomoda M et al (1998) Long-term survival of patients with stage IV gastric carcinoma. Cancer 82(12):2307–2311PubMedCrossRefGoogle Scholar
  3. 3.
    Isobe Y, Nashimoto A, Akazawa K et al (2011) Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer 14(4):301–316PubMedCrossRefGoogle Scholar
  4. 4.
    Maruyama K, Kaminishi M, Hayashi K et al (2006) Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer 9(2):51–66PubMedCrossRefGoogle Scholar
  5. 5.
    Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221PubMedCrossRefGoogle Scholar
  6. 6.
    Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697PubMedCrossRefGoogle Scholar
  7. 7.
    Maehara Y, Hasuda S, Koga T et al (2000) Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 87(3):353–357PubMedCrossRefGoogle Scholar
  8. 8.
    Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810–1820PubMedCrossRefGoogle Scholar
  9. 9.
    Koga R, Yamamoto J, Ohyama S et al (2007) Liver resection for metastatic gastric cancer: experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol 37(11):836–842PubMedCrossRefGoogle Scholar
  10. 10.
    Sakamoto Y, Ohyama S, Yamamoto J et al (2003) Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery 133(5):507–511PubMedCrossRefGoogle Scholar
  11. 11.
    Shirabe K, Wakiyama S, Gion T et al (2006) Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literature. HPB (Oxford) 8(2):89–92CrossRefGoogle Scholar
  12. 12.
    Tokunaga M, Ohyama S, Hiki N et al (2010) Can super extended lymph node dissection be justified for gastric cancer with pathologically positive para-aortic lymph nodes? Ann Surg Oncol 17(8):2031–2036PubMedCrossRefGoogle Scholar
  13. 13.
    Sarela AI, Miner TJ, Karpeh MS et al (2006) Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg 243(2):189–195PubMedCrossRefGoogle Scholar
  14. 14.
    Sarela AI, Yelluri S (2007) Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? Arch Surg 142(2):143–149 discussion 149PubMedCrossRefGoogle Scholar
  15. 15.
    Hartgrink HH, Putter H, Klein Kranenbarg E et al (2002) Value of palliative resection in gastric cancer. Br J Surg 89(11):1438–1443PubMedCrossRefGoogle Scholar
  16. 16.
    Kim KH, Lee KW, Baek SK et al (2011) Survival benefit of gastrectomy +/− metastasectomy in patients with metastatic gastric cancer receiving chemotherapy. Gastric Cancer 14(2):130–138PubMedCrossRefGoogle Scholar
  17. 17.
    Yonemura Y, Kawamura T, Bandou E et al (2005) Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 92(3):370–375PubMedCrossRefGoogle Scholar
  18. 18.
    Ouchi K, Sugawara T, Ono H et al (1998) Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol 69(1):41–44PubMedCrossRefGoogle Scholar
  19. 19.
    Kim DY, JooJK Park YK et al (2008) Is palliative resection necessary for gastric carcinoma patients? Langenbecks Arch Surg 393(1):31–35PubMedCrossRefGoogle Scholar
  20. 20.
    Kahlke V, Bestmann B, Schmid A et al (2004) Palliation of metastatic gastric cancer: impact of preoperative symptoms and the type of operation on survival and quality of life. World J Surg 28(4):369–375. doi:10.1007/s00268-003-7119-0 PubMedCrossRefGoogle Scholar
  21. 21.
    Doglietto GB, Pacelli F, Caprino P et al (2000) Surgery: independent prognostic factor in curable and far advanced gastric cancer. World J Surg 24(4):459–463. doi:10.1007/s002689910073 discussion 464PubMedCrossRefGoogle Scholar
  22. 22.
    Yook JH, Oh ST, Kim BS (2005) Clinicopathological analysis of Borrmann type IV gastric cancer. Cancer Res Treat 37(2):87–91PubMedCrossRefGoogle Scholar
  23. 23.
    Li C, Yan M, Chen J et al (2010) Survival benefit of non-curative gastrectomy for gastric cancer patients with synchronous distant metastasis. J Gastrointest Surg 14(2):282–288PubMedCrossRefGoogle Scholar
  24. 24.
    Chang YR, Han DS, Kong SH et al (2012) The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol 19(4):1231–1239PubMedCrossRefGoogle Scholar
  25. 25.
    Japanese Gastric Cancer Association (1998) Japanese Classification of Gastric Carcinoma—2nd English Edition. Gastric Cancer 1(1):10–24PubMedCrossRefGoogle Scholar
  26. 26.
    Japanese Research Society for Gastric Cancer (1995) Japanese classification of gastric carcinoma, 1st English edn. Kanehara & Co, TokyoGoogle Scholar
  27. 27.
    Sobin L, Wittekind D (eds) (2002) TNM classification of malignant tumors, vol 6. Wiley, New YorkGoogle Scholar
  28. 28.
    Lin SZ, Tong HF, You T et al (2008) Palliative gastrectomy and chemotherapy for stage IV gastric cancer. J Cancer Res Clin Oncol 134(2):187–192PubMedCrossRefGoogle Scholar
  29. 29.
    Hioki M, Gotohda N, Konishi M et al (2010) Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg 34(3):555–562. doi:10.1007/s00268-010-0396-5 PubMedCrossRefGoogle Scholar
  30. 30.
    Kim SJ, Kim HH, Kim YH et al (2009) Peritoneal metastasis: detection with 16- or 64-detector row CT in patients undergoing surgery for gastric cancer. Radiology 253:407–415PubMedCrossRefGoogle Scholar
  31. 31.
    Shim JH, Yoo HM, Lee HH et al (2011) Use of laparoscopy as an alternative to computed tomography (CT) and positron emission tomography (PET) scans for the detection of recurrence in patients with gastric cancer: a pilot study. Surg Endosc 25:3338–3344PubMedCrossRefGoogle Scholar
  32. 32.
    Tsuchida K, Yoshikawa T, Tsuburaya A et al (2011) Indications for staging laparoscopy in clinical T4M0 gastric cancer. World J Surg 35:2703–2709. doi:10.1007/s00268-011-1290-5 PubMedCrossRefGoogle Scholar
  33. 33.
    Fujitani K, Yang HK, Kurokawa Y et al (2008) Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol 38(7):504–506PubMedCrossRefGoogle Scholar
  34. 34.
    Russell RC, Treasure T (2012) Counting the cost of cancer surgery for advanced and metastatic disease. Br J Surg 99:449–450PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2012

Authors and Affiliations

  • Masanori Tokunaga
    • 1
  • Masanori Terashima
    • 1
  • Yutaka Tanizawa
    • 1
  • Etsuro Bando
    • 1
  • Taiichi Kawamura
    • 1
  • Hirofumi Yasui
    • 2
  • Narikazu Boku
    • 2
  1. 1.Division of Gastric SurgeryShizuoka Cancer CenterSunto-gun, ShizuokaJapan
  2. 2.Division of Gastrointestinal OncologyShizuoka Cancer CenterShizuokaJapan

Personalised recommendations